8 results about "Artificial tears" patented technology

The invention relates to the technical field of medical preparations, in particular to moisturizing and repairing type artificial tear as well as a preparation method and application thereof. Comprising the following steps: preparing effective components including high-molecular-weight polydeoxyribonucleotide and hyaluronic acid or a salt thereof into a homogeneous-phase stable composite solution, sterilizing, filtering, and aseptically packaging, the artificial tear formed by selecting high-molecular-weight polydeoxyribonucleotide and high-molecular-weight sodium hyaluronate as effective components has a relatively good repairing effect on tissues, can form long-term moisturizing and lubrication on ocular surfaces, is suitable for treating xerophthalmia, repairing cornea, relieving inflammatory response and the like, and has a good application prospect. Important market values and clinical application prospects are realized.

The present invention relates to ophthalmic formulations comprising N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide hemihydrate polyethylene glycol and artificial tear solutions, and to processes for preparing said ophthalmic formulations.

The invention discloses an intelligent dry-eye-preventing contact lens for monitoring and adjusting tears in real time. The intelligent dry-eye-preventing contact lens comprises an external radio frequency transmitter, a flexible circuit module and a flexible substrate with a detection bin and a medicine bin, the radio frequency transmitter transmits 100-200MHz radio frequency electromagnetic waves, the flexible circuit module is embedded into the flexible substrate and is integrated with a coupling coil L1, an MCU, a Bluetooth module, a sensing module and a medicine discharging module, wireless energy supply is achieved through electromagnetic induction, the sensing module collects tear data, and the medicine discharging module controls the medicine bin to release artificial tears; the flexible substrate integrates the detection bin and the medicine bin, and the opening of the medicine bin is provided with a tridecanoic acid packaging layer. Closed-loop management of real-time tear monitoring and accurate artificial tear release under wireless energy supply is achieved, a battery is not needed, the system is lighter, thinner and safer, remote monitoring is facilitated through real-time data feedback, xerophthalmia is effectively prevented and intervened through accurate drug release, and the technical blank of dynamic tear management and contact lens integrated diagnosis and treatment is filled up.

The invention relates to the technical field of medical instruments, in particular to an atomization device for xerophthalmia treatment, which comprises a control box and a control panel, the control panel is mounted on the outer surface of the control box, a guide mechanism is arranged on the control box, a connecting frame is connected to the guide mechanism, and the guide mechanism is used for guiding liquid medicine into the connecting frame. An atomizer and eyeshades are installed on the connecting frame, the atomizer is used for atomizing liquid medicine and discharging the liquid medicine into the eyeshades, silica gel rings are connected to the eyeshades, and a connecting belt is connected between the two eyeshades. A plurality of second butt joint pipes, a control mechanism (comprising a round block with a channel and a knob frame) and a reset mechanism (comprising a spring, a lifting frame and a limiting rod) are arranged in the control box, so that liquid medicine (such as artificial tears, anti-inflammatory drugs, repair factors and the like) with different functions can be selected and automatically switched according to needs in a treatment process; treatment interruption or manual liquid medicine replacement is not needed, the risk of cross contamination is effectively avoided, and treatment compliance and clinical efficiency are improved.

This application relates to an artificial tear solution and a method for characterizing the protein removal effect of contact lens solution. The artificial tear solution comprises the following components: PBS buffer, lysozyme, sodium hyaluronate, and sodium formate. This invention effectively prevents protein denaturation and improves the stability of the artificial tear solution by adding sodium formate to a conventional artificial tear solution. The addition of sodium hyaluronate makes the protein more difficult to wash off, thereby effectively improving the adhesion of proteins to RGP lenses. Furthermore, the drying process further fixes the protein, thus enabling a more accurate characterization of the protein removal effect of the contact lens solution.

The present invention relates to ophthalmic compositions in the form of oil-in-water (O / W) nano-emulsions, and which mainly comprise propylene glycol and sodium hyaluronate. The invention also relates to preparation methods and uses of the artificial tear compositions.

An oxygen-permeable contact lens comprises a contact lens body, the contact lens body is provided with a convex-arc-shaped outer lens face and a concave-arc-shaped inner lens face located on the opposite side of the outer lens face, and the contact lens body is provided with at least one oxygen-permeable hole which linearly penetrates through the outer lens face and the inner lens face through laser. The air permeability and the oxygen permeation rate of the contact lens are increased by utilizing the oxygen permeation holes, so that when the contact lens is worn, eyeballs can obtain oxygen through the oxygen permeation holes in time, the circulation effect of tears and moisture is improved, uncomfortable symptoms such as eye dryness, stabbing pain or foreign body sensation are greatly reduced, and the wearing comfort is further improved; in addition, eye drops or artificial tears can be used, an eyeball wetting effect can be really achieved through the oxygen permeation holes, and the eye drops or the artificial tears have the convenience of relieving the eyeballs.

The application discloses an eye nanoemulsion preparation for treating immune dry eye and a preparation method thereof, and the preparation comprises a nanoemulsion inner core loaded with tacrolimus or cyclosporine A, a simulated tear protein composite layer fixed on an oil-water interface through an amide bond, and surface modified hyaluronic acid oligosaccharide. The protein composite layer is covalently crosslinked by lysozyme and lactoferrin at an optimized molar ratio of 1:(0.8-1.2), and the hyaluronic acid is connected to the epsilon-amino group of the protein through an amide bond after EDC / NHS activation. The preparation achieves three breakthrough effects: the drug first-order release rate constant k is less than or equal to 0.25 h ‑1 in artificial tears, the drug efficacy lasts for 8-12 hours, the corneal retention time is more than 4.8 hours, the specific binding of the charge-neutral surface and mucin is relied on, the lysozyme activity retention rate is greater than or equal to 85%, and the HET-CAM irritation score is less than or equal to 0.8, thereby significantly improving the treatment safety and biocompatibility. Finally, the core advantage that the eye surface immune response and the microenvironment repair can be simultaneously inhibited through 1-2 times of daily administration is achieved.